Legs were covered with psoriasis again; Pain during injection; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Legs were covered with psoriasis again) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) solution for injection for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis.   In April 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) Pre-filled pen. On an unknown date, the patient experienced PSORIASIS (Legs were covered with psoriasis again) (seriousness criterion medically significant) and INJECTION SITE PAIN (Pain during injection). At the time of the report, PSORIASIS (Legs were covered with psoriasis again) outcome was unknown and INJECTION SITE PAIN (Pain during injection) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient reported that he used the pen for this first time in Feb and it hurt. It only lasted about five minutes. He was previously doing the syringe. In Apr-2021, he had COVID vaccine and he felt like the Skyrizi hasn't been working as well.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant medications were reported. No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  CC: This spontaneous case concerns an adult, male patient with an underlying condition of chronic plaque psoriasis treated with Risankizumab, who experienced an unexpected, medically significant event of Psoriasis flare-up after receiving a dose of mRNA-1273 vaccine. Exactly onset latency of the event psoriasis flare-up relative to vaccination cannot be determined with unknown event's onset date and vaccination date. Reportedly, patient had previously been clear of psoriasis, but the front of his legs was covered with psoriasis again. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patients with an underlying chronic plaque psoriasis may experience flare-ups with various triggers. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement.; Sender's Comments: This spontaneous case concerns an adult, male patient with an underlying condition of chronic plaque psoriasis treated with Risankizumab, who experienced an unexpected, medically significant event of Psoriasis flare-up after receiving a dose of mRNA-1273 vaccine. Exactly onset latency of the event psoriasis flare-up relative to vaccination cannot be determined with unknown event's onset date and vaccination date. Reportedly, patient had previously been clear of psoriasis, but the front of his legs was covered with psoriasis again. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patients with an underlying chronic plaque psoriasis may experience flare-ups with various triggers. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement.